Subscribe

Sonova Holding AG (SOON.SW)

CHF208.00 +3.60 (+1.76%)
CH SIX Healthcare Medical - Devices
Address Laubisrutistrasse 28 8712
Stäfa, CH
CEO Eric Bernard
Website sonova.com
IPO 2001-09-24
ISIN CH0012549785

Explore sections of this company profile

Also trades on London Stock Exchange · 0QPY.L (CHF) Other OTC · SONVF (USD) Other OTC · SONVY (USD) Swiss Exchange · SOON.SW (CHF)
Description

Headquartered in Stäfa, Switzerland, Sonova Holding AG is a leading provider of innovative hearing care solutions for both adults and children. The company's operations are divided into two primary segments: Hearing Instruments and Cochlear Implants. Sonova's extensive offerings include advanced wireless communication devices, rechargeable hearing aids, wireless headsets, speech-enhanced hearables, premium audiophile headphones, microphones, and wireless transmission systems, alongside comprehensive audiological care services. Its renowned hearing aid brands comprise Phonak, Unitron, and Hansaton, while Advanced Bionics is its flagship for cochlear implants. For consumer audio, Sonova offers products under the Sennheiser brand. The company delivers its audiological care through a vast network of around 3,600 clinics and stores operating under various regional names such as AudioNova, Audium, and Boots Hearingcare, among others. Additionally, its products are distributed via independent partners. Sonova boasts a significant international presence, serving markets across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Founded in 1947, the company was formerly known as Phonak Holding AG before officially changing its name to Sonova Holding AG in August 2007.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CHF208.00 +3.60 (+1.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
166.3K
Beta
1.07
Float Shares
48.89M
Free Float %
82.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.50% +15.67% +8.21% +3.57% +4.69% -2.54% -27.94% -20.02% -31.74% +57.68% +651.30%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (1 ratings, all time) Sell
Price Targets & DCF
Current price
208.00
DCF (Unlevered) 221.41 +6.4%
DCF (Levered) 204.67 -1.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 37% Bullish
Rating 2026-05 Change
Strong Buy 4 0
Buy 3 0
Hold 8 0
Sell 3 0
Strong Sell 1 0
Quality scores
Altman Z-Score
5.97
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Devices: +11.2%
    -6.7% Q1'26: -4.5% (vs Q1'24)
  • ✗
    EPS growth Medical - Devices: +28.5%
    -0.2% Q1'26: -1.7% (vs Q1'24)
  • ✓
    FCF margin FCF growth · Medical - Devices: +30.9%
    +73.7% ★ Q1'26: +11.3% (vs Q1'24)
  • ✓
    EBIT margin Medical - Devices: +6.2%
    +73.7% ★ Q1'26: +77.2% (vs Q1'24)
  • ✓
    ROIC Medical - Devices: +3.3%
    —
  • ✗
    Share dilution Medical - Devices: 0.0%
    +1.3% Q1'26: +1.0% (vs Q1'24)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    — Q1'26: 0.34× (vs Q1'24)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.07) × ERP
WACC = 0% × Ke + 0% × Kd (4.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 208.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2012
actual 		Mar 2013
actual 		Mar 2014
actual 		Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
16 Rev. Ana.
15 EPS Ana. 		Mar 2027
11 Rev. Ana.
13 EPS Ana. 		Mar 2028
14 Rev. Ana.
13 EPS Ana. 		Mar 2029
7 Rev. Ana.
6 EPS Ana. 		Mar 2030
3 Rev. Ana.
2 EPS Ana. 		Mar 2031
5 Rev. Ana.
3 EPS Ana.
Revenue
1.62B
est: 1.66B (-2.2%)
1.80B
est: 1.85B (-2.9%)
1.95B
est: 1.98B (-1.2%)
2.04B
est: 2.05B (-0.8%)
2.07B
est: 2.11B (-1.8%)
2.40B
est: 2.38B (+0.5%)
2.65B
est: 2.67B (-1.0%)
2.76B
est: 2.76B (0.0%)
2.92B
est: 2.93B (-0.3%)
2.60B
est: 2.59B (+0.3%)
3.36B
est: 3.33B (+1.0%)
3.74B
est: 3.78B (-1.0%)
3.63B
est: 3.66B (-0.9%)
3.87B
est: 3.84B (+0.5%)
3.72B
3.58B – 3.86B
-3.2% YoY
3.84B
3.72B – 4.04B
+3.1% YoY
4.09B
3.85B – 4.35B
+6.6% YoY
4.35B
4.34B – 4.36B
+6.3% YoY
4.54B
4.33B – 4.80B
+4.3% YoY
4.81B
4.59B – 5.09B
+5.9% YoY
EBITDA
366.07M
est: 366.78M (-0.2%)
233.93M
est: 401.78M (-41.8%)
474.10M
est: 244.90M (+93.6%)
495.75M
est: 486.08M (+2.0%)
462.64M
est: 512.06M (-9.7%)
522.23M
est: 542.03M (-3.7%)
607.30M
est: 592.39M (+2.5%)
660.20M
est: 629.21M (+4.9%)
711.00M
est: 693.15M (+2.6%)
818.60M
est: 585.77M (+39.7%)
893.10M
est: 641.56M (+39.2%)
974.50M
est: 710.12M (+37.2%)
917.90M
est: 852.78M (+7.6%)
927.00M
est: 1.02B (-9.5%)
993.10M
954.33M – 1.03B
-3.0% YoY
1.02B
991.52M – 1.08B
+3.1% YoY
1.09B
1.03B – 1.16B
+6.6% YoY
1.16B
1.16B – 1.16B
+6.3% YoY
1.21B
1.16B – 1.28B
+4.3% YoY
1.28B
1.22B – 1.36B
+5.9% YoY
EBIT
287.76M
est: 274.45M (+4.8%)
154.38M
est: 321.18M (-51.9%)
404.63M
est: 167.43M (+141.7%)
424.07M
est: 421.77M (+0.5%)
387.94M
est: 442.19M (-12.3%)
426.77M
est: 456.44M (-6.5%)
495.10M
est: 478.89M (+3.4%)
532.00M
est: 498.23M (+6.8%)
509.10M
est: 569.08M (-10.5%)
618.00M
est: 429.90M (+43.8%)
749.80M
est: 470.85M (+59.2%)
739.00M
est: 521.17M (+41.8%)
675.50M
est: 625.87M (+7.9%)
678.50M
est: 759.57M (-10.7%)
736.48M
707.73M – 763.36M
-3.0% YoY
759.38M
735.30M – 799.11M
+3.1% YoY
809.43M
761.47M – 860.59M
+6.6% YoY
860.70M
857.99M – 863.41M
+6.3% YoY
897.86M
856.69M – 949.86M
+4.3% YoY
951.20M
907.58M – 1.01B
+5.9% YoY
Net Income
246.76M
est: 234.12M (+5.4%)
110.92M
est: 275.52M (-59.7%)
340.83M
est: 118.50M (+187.6%)
359.99M
est: 355.79M (+1.2%)
337.03M
est: 371.01M (-9.2%)
349.17M
est: 381.31M (-8.4%)
400.14M
est: 394.68M (+1.4%)
454.10M
est: 412.77M (+10.0%)
483.20M
est: 481.95M (+0.3%)
581.00M
est: 407.31M (+42.6%)
649.00M
est: 446.11M (+45.5%)
647.50M
est: 647.50M (+0.0%)
601.00M
est: 601.00M (+0.0%)
540.50M
est: 540.50M (+0.0%)
529.25M
423.70M – 630.74M
-2.1% YoY
607.27M
535.89M – 669.86M
+14.7% YoY
670.68M
616.22M – 744.17M
+10.4% YoY
727.36M
725.55M – 871.74M
+8.5% YoY
851.35M
800.59M – 915.44M
+17.0% YoY
906.91M
852.85M – 975.19M
+6.5% YoY
SGA
672.02M
est: 693.02M (-3.0%)
740.16M
est: 750.20M (-1.3%)
784.85M
est: 790.90M (-0.8%)
814.26M
est: 819.42M (-0.6%)
832.46M
est: 839.17M (-0.8%)
1.06B
est: 941.84M (+12.3%)
1.20B
est: 1.14B (+5.6%)
1.28B
est: 1.19B (+7.9%)
1.34B
est: 1.32B (+1.8%)
1.13B
est: 1.13B (+0.2%)
1.41B
est: 1.24B (+13.7%)
1.65B
est: 1.37B (+20.3%)
1.70B
est: 1.64B (+3.4%)
1.86B
est: 1.72B (+7.8%)
1.67B
1.61B – 1.73B
-3.0% YoY
1.72B
1.67B – 1.81B
+3.1% YoY
1.84B
1.73B – 1.95B
+6.6% YoY
1.95B
1.95B – 1.96B
+6.3% YoY
2.04B
1.94B – 2.15B
+4.3% YoY
2.16B
2.06B – 2.28B
+5.9% YoY
EPS
3.69
est: 4.10 (-9.9%)
1.64
est: 4.24 (-61.3%)
5.08
est: 5.42 (-6.2%)
5.37
est: 5.56 (-3.4%)
5.11
est: 5.32 (-4.0%)
5.35
est: 5.67 (-5.7%)
6.11
est: 6.40 (-4.5%)
6.95
est: 7.30 (-4.8%)
7.56
est: 8.56 (-11.7%)
9.23
est: 7.22 (+27.9%)
10.42
est: 11.02 (-5.4%)
10.75
est: 10.87 (-1.1%)
10.08
est: 9.79 (+3.0%)
9.07
est: 9.82 (-7.7%)
9.58
7.09 – 10.55
-2.5% YoY
10.45
8.96 – 11.20
+9.1% YoY
11.57
10.31 – 12.45
+10.7% YoY
12.96
12.14 – 14.58
+12.1% YoY
14.24
13.39 – 15.31
+9.9% YoY
15.17
14.27 – 16.31
+6.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-20 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-05-19 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-18 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-15 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-05-13 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-05-12 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-05-11 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-05-08 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-05-07 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-05-06 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-05-05 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-05-04 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-30 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-29 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-28 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-27 A- 4/5 4/5 5/5 5/5 1/5 3/5 2/5
2026-04-24 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-23 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-22 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-21 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-20 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-17 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-16 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5
2026-04-15 B+ 3/5 4/5 5/5 5/5 1/5 2/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.38B
OE per share TTM
23.05
Owner's Yield
11.24%
Maintenance CapEx ratio
14.02%
Maint CapEx / Avg PPE
15.8%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
1
Total invested
1.02M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2025 Q3
Investors holding
1
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 BOSTON COMMON ASSET MANAGEMENT, LLC — -3.7K (-100.0%) — -1.0M (-100.0%) 0.00% -0.006 pp 0.00% -0.029 pp CHF— 12 qtrs SOLD
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock Held by 334 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares SMIM ETF (CH) CSSMIM.SW 3.53% 52.28M 0.45%
2 First Trust International Developed Capital Strength ETF FICS 2.02% 4.37M 0.70%
3 First Trust Switzerland AlphaDEX Fund FSZ 1.55% 575.8K 0.80%
4 iShares MSCI Europe Quality Dividend Advanced UCITS ETF EQDS.L 1.05% 9.95M 0.28%
5 iShares SLI UCITS ETF (DE) EXI1.DE 1.02% 6.67M 0.51%
6 iShares SLI ETF (CH) CSSLI.SW 1.02% 9.32M 0.35%
7 Global X - Aging Population ETF AGNG 1.01% 868.9K 0.50%
8 Xtrackers SLI UCITS ETF 1D DXS0.DE 0.97% 5.70M 0.25%
9 iShares MSCI Switzerland ETF EWL 0.88% 18.73M 0.50%
10 Distillate International Fundamental Stability & Value ETF DSTX 0.86% 432.2K 0.55%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
145.0K
Shares Outstanding
59.40M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Arnd Kaldowski Advisor 2M male
Anders Rosengren Chief Research & Development Officer and Member of Management Board — male
Andreas Schmidlechner Chief Retail Excellence Officer — male
Bernd Wagner President of Asia Pacific Region (excluding China) — male
Bjorn Christ Chief Strategy Officer — male
Elodie Carr-Cingari Chief Financial Officer — female
Eric Bernard Chief Executive Officer — male
Fabia Meline Muller Launch Program Manager — female
Fang Fang President of China Region — female
Franz Brand Chief Legal & Compliance Officer — male
Jacqueline Drexler Audiology Manager — female
Jan Metzdorff President of Hearing Instruments Wholesale for US — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Devices